¡Nuestra primera publicación como grupo cooperativo! RENO Study: Clinical characteristics, treatment patterns and survival in RCC sciencedirect.com/science/articl…

#APCCC24

K. Fizazi - Choosing the best option in mCRPC after triplet therapy in the mHSPC setting. Practical guidance

UroToday.com

Deep down, even the proponents of invalid and untested surrogate endpoints, know that OS matters. That’s why there is (appropriate) celebration when a drug improves OS but I wonder where that acknowledgment of the importance of OS endpoint disappears when cheerleading marginal…

1/ The long-awaited OS results from #KEYNOTE -564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC .

nejm.org/doi/full/10.10…

Just published with the #AACR24 Clinical Plenary presentation: CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell #Carcinoma , by Sumanta K. Pal, MD, FASCO et al.
bit.ly/3J5jzTH
City of Hope AACR

$IPH.PA anti-Nectin-4 ADC IPH45. Let's hear it for topo1 inhibitor payloads and hydrophilic, cleavable linkers (+bonus point for 'bystander effect') #AACR24

Ayudar a ser madres a las mujeres con enfermedades autoinmunes, objetivo de la nueva unidad del HUCA lne.es/asturias/2024/… a través de La Nueva España
R. Coto H.

EV-302 is published today in the NEJM

Despite the gr8t results of the trial, the paper is accompanied with an editorial from Günter Niegisch with a mention on financial toxicity that can not be dismissed…

Costs will be paramount to get this combination approved in many countries.

Ese cameo del autor de #ReinaRoja al inicio del capitulo 3 en la serie de @AmazonStudios
Juan Gómez-Jurado

“Se nos ha colado un puto troll” 🤣

⚕️El servicio de oncología médica de @HUCA evalúa a los pacientes con sospecha de cáncer en menos de cinco días
⚕️Es un servicio sin lista de espera que cerró 2023 con 33.132 consultas atendidas y 25.256 tratamientos en el hospital de día oncohematológico.

Great, great, great!!! 👏👏🙏

This is blowing up my mind.

From “A New Look at P Values for Randomized Clinical Trials”. NEJM Evid 2024;3(1)

evidence.nejm.org/doi/full/10.10…

Como declaración de principios y tras el “día de”:

yo no estoy en ninguna trinchera.

The insights from ASCO GU 2024 keep coming! 💫

LARVOL CLIN analyzed key discussions from 2500+ leading oncologists on X, curating a list of the top influencers and their impact.

Explore key takeaways from the conference here: bit.ly/4bf5m34

#GU24 #LARVOL #Oncology